CLINICAL TRIALS PROFILE FOR ROCEPHIN

All Clinical Trials for ROCEPHIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00035347 ↗	Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia	Completed	Pfizer	Phase 4	2001-01-01	A trial in which patients over 18 years of age who are hospitalized with community acquired pneumonia and are otherwise eligible for entry into the study are randomly selected to receive one of two treatment regimens. After written informed consent is obtained, patients will receive one of the following two treatment regimens: 1) intravenous administration of azithromycin and ceftriaxone followed by azithromycin tablets, or 2) intravenous administration of levofloxacin followed by levofloxacin tablets. At least four study visits are normally conducted up to approximately one month after starting therapy. The objective of this study is to compare the safety and efficacy of the two treatment regimens.
NCT00037479 ↗	Brain Imaging and Retreatment Study of Persistent Lyme Disease	Completed	National Institute of Neurological Disorders and Stroke (NINDS)	Phase 2	1999-12-01	The purpose of this study is to determine whether patients with persistent memory problems after Lyme disease benefit from an additional longer course of IV antibiotic therapy; to use modern brain imaging technology to determine whether the problem in the central nervous system is primarily one of poor blood flow or one of impaired nerve cell functioning; and to try to identify biological markers prior to treatment that will identify patients who are more or less likely to respond to the study treatment.
NCT00538694 ↗	Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia	Completed	Cubist Pharmaceuticals LLC	Phase 3	2000-10-31	To evaluate the safety and efficacy of daptomycin in adults who have pneumonia due to Streptococcus pneumoniae.
NCT00540072 ↗	Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae	Completed	Cubist Pharmaceuticals LLC	Phase 3	2001-07-30	A COMPARASON OF CIDECIN™ (DAPTOMYCIN) TO ROCEPHIN® (CEFTRIAXONE) IN THE TREATMENT OF MODERATE TO SEVERE COMMUNITY-ACQUIRED ACUTE BACTERIAL PNEUMONIA DUE TO S. PNEUMONIAE
NCT00566111 ↗	Ceftriaxone in the Management of Bipolar Depression	Terminated	Stanley Medical Research Institute	N/A	2007-09-01	We aim to study the efficacy of intravenous ceftriaxone in a four-week, inpatient, placebo-controlled, double-blind study, as an augmentation therapy in patients with bipolar disorder, currently depressed, who have failed to respond to conventional treatments.
NCT00566111 ↗	Ceftriaxone in the Management of Bipolar Depression	Terminated	Yale University	N/A	2007-09-01	We aim to study the efficacy of intravenous ceftriaxone in a four-week, inpatient, placebo-controlled, double-blind study, as an augmentation therapy in patients with bipolar disorder, currently depressed, who have failed to respond to conventional treatments.
NCT00838864 ↗	Comparison of 3 Days and 7 Days Intravenous Ceftriaxone Prophylaxis for Variceal Bleeding	Completed	Far Eastern Memorial Hospital	Phase 4	2009-03-01	Prophylactic antibiotics have been routinely recommended for cirrhotic patients with upper gastrointestinal bleeding recently. However, the regimen and duration of its use remain an inconclusive issue. Quinolones and 3rd generation cephalosporins have been more often used for prophyalxis recently. The duration for antibiotic usage were variable in the literatures, ranged from 4-10 days. The latest guideline from AASLD in 2007 was 7 days. In the survey of infections in cirrhotic patients with UGI bleeding performed by Bernard et al, most infections occurred in the first 5 days and half within the first 48 hours. Therefore, considering the cost-effectiveness and drug resistance issues, the necessity for such prophylaxis for 7 days may need to be re-evaluated. The purpose of our study is to investigate the antibiotic prophylaxis duration for cirrhotic patients with acute gastro-esophageal variceal bleeding. We will enroll those patients suffering from variceal bleeding documented by endoscopic examination and without apparent evidence of infection. Those who have received antibiotics within 2 weeks, are less than 18 years old, get pregnant, have malignancy other than HCC, have allergy to ceftrioxone are excluded. After receiving well explanation and giving consent, these patients are randomly allocated to 2 groups and receive prophylactic antibiotic just after endoscopic examination; Group I: receiving ceftriaxone 500 mg iv bolus stat and then q12h for 3 days, Group II: receiving ceftriaxone 500 mg iv bolus stat and then q12h for 7 days. They will receive appropriate endoscopic treatment for gastro-esophgeal varices and glypressin 1mg q6h for 3 days. They will start to feed on the 2nd day if not contraindicated. The 2nd endoscopic treatment for varices will be performed 2 weeks later. We record the demographic data, vital signs, transfusion amount; check hemogram, U/A, CXR, ascites routine (with apparent ascites), classification of variceal size and Child-Pugh classification. We monitor the events of rebleeding & infection, transfusion amount and hospitalization days We use rebleeding rate within 14 days as the primary end point. It is defined as the following events after initial stabilization of vital signs for 24 hours; (1): recurrence of hematemesis or bloody stool (2); need of transfusion more than 2 unit of blood and systolic pressure < 100 mmHg or pulse rate > 100/mn. We use infection rate during admission and mortality rate within 28 days as secondary end points.

Clinical Trial Conditions for ROCEPHIN

Condition Name

Condition Name for ROCEPHIN
Intervention	Trials
Pneumonia, Bacterial	2
Hip Prosthetic Joint Infection	1
Cirrhosis, Liver	1
Intra-abdominal Infections	1

Condition MeSH

Condition MeSH for ROCEPHIN
Intervention	Trials
Infection	3
Pneumonia	3
Infections	3
Pneumonia, Bacterial	2

Clinical Trial Locations for ROCEPHIN

Trials by Country

Trials by Country for ROCEPHIN
Location	Trials
United States	21
Japan	15
Canada	6
Taiwan	3
France	2

Trials by US State

Trials by US State for ROCEPHIN
Location	Trials
Pennsylvania	2
Ohio	2
New York	2
Michigan	2
California	2

Clinical Trial Progress for ROCEPHIN

Clinical Trial Phase

Clinical Trial Phase for ROCEPHIN
Clinical Trial Phase	Trials
Phase 4	8
Phase 3	4
Phase 2	6

Clinical Trial Status

Clinical Trial Status for ROCEPHIN
Clinical Trial Phase	Trials
Completed	9
Unknown status	4
Recruiting	3

Clinical Trial Sponsors for ROCEPHIN

Sponsor Name

Sponsor Name for ROCEPHIN
Sponsor	Trials
Pfizer	3
Cubist Pharmaceuticals LLC	2
Far Eastern Memorial Hospital	1

Sponsor Type

Sponsor Type for ROCEPHIN
Sponsor	Trials
Other	35
Industry	7
NIH	2

ROCEPHIN Market Analysis and Financial Projection

Last updated: April 25, 2026

ROCEPHIN (ceftriaxone): Clinical Trial Status, Market Readout, and Projection

What is ROCEPHIN and what is its current clinical relevance?

ROCEPHIN is the brand name of ceftriaxone, a third-generation cephalosporin antibiotic. It is widely used for bacterial infections across inpatient and outpatient settings, including community-acquired and hospital-acquired indications where susceptibility supports use.

Because ceftriaxone is an established, off-patent antibiotic in most jurisdictions, the clinical landscape is dominated by:

• Newer guideline-driven utilization and stewardship patterns rather than novel phase-3 registration trials for the drug substance itself
• Comparative and observational studies (e.g., dose optimization, site-of-infection outcomes, resistance and stewardship impact)
• Formulation and delivery research that is often not tied to brand-level ROCEPHIN exclusivity

Bottom line for clinical trials: the “signal” for ROCEPHIN is less about new approvals and more about how ceftriaxone remains positioned in standard-of-care pathways for bacterial infections while antimicrobial resistance patterns and stewardship constraints shift usage volumes.

---

What does the clinical trials update look like for ceftriaxone/ROCEPHIN?

Clinical-trials activity for ceftriaxone typically clusters in three categories:

1. Comparative efficacy/safety trials

   • Common comparators include other beta-lactams (cefotaxime, piperacillin-tazobactam), carbapenems in severe infections, and sometimes fluoroquinolones depending on syndrome and setting.
   • Endpoints generally track clinical cure, microbiologic eradication, time-to-defervescence, length of stay, and adverse events.

2. Dose-optimization and pharmacokinetic (PK) studies

   • PK work centers on achieving target exposures in specific populations (e.g., pediatric, renal impairment, critically ill) and on dosing strategies for severe infections.
   • These studies influence guideline recommendations and local protocols, affecting utilization more than product-level market share.

3. Stewardship and resistance surveillance-linked studies

   • Trials and real-world analyses often examine outcomes under stewardship interventions that restrict broad-spectrum beta-lactams and monitor resistance trends.

Implication for market modeling: trial “updates” for ceftriaxone generally translate into usage behavior shifts rather than brand-level differentiation.

---

How does the market view ceftriaxone today?

Ceftriaxone is a core antibiotic on hospital formularies and is also used in outpatient settings under guideline pathways and susceptibility-driven prescribing. The market for ROCEPHIN-like offerings is shaped by:

• Generic price competition (multi-source, low-cost supply)
• Procurement protocols that prioritize lowest-cost therapeutics that meet formulary standards
• Inventory and tendering cycles in institutional healthcare
• Antimicrobial stewardship controls that affect which empiric regimens clinicians choose and how often ceftriaxone is selected versus alternatives

In practice, “ROCEPHIN market performance” is constrained by the fact that ceftriaxone is not a patented product in most major markets, so brand-level pricing power is limited and volume share depends on contracting and supply reliability rather than exclusivity.

---

What are the competitive dynamics behind ROCEPHIN revenue?

Ceftriaxone competes primarily with:

• Other injectable beta-lactams (broader-spectrum or more targeted agents depending on syndrome)
• Carbapenems for severe resistant pathogens (often selected when susceptibility indicates)
• Other cephalosporins and combination regimens under local resistance patterns

ROCEPHIN competes mostly on:

• Tender pricing
• Supply continuity
• Formulary inclusion
• Clinician familiarity and institutional preferences

This structure makes the market less sensitive to incremental clinical trial outcomes and more sensitive to:

• hospital purchasing behavior
• antimicrobial resistance trends
• reimbursement dynamics
• short-term supply constraints or pricing resets

---

Market projection: what trajectory should investors model for ROCEPHIN-like ceftriaxone brands?

Without proprietary brand-level sales disclosure, the market projection must be modeled at the ceftriaxone class level with adjustments for brand share under tendering.

A practical projection framework for an off-patent antibiotic brand should model:

1) Volume (units)

• Stable baseline demand driven by common bacterial infection indications
• Downward pressure from stewardship and increasing preference for narrow-spectrum regimens when pathogen identification supports de-escalation
• Upside pockets from waves of infectious disease burden (seasonality and outbreak-related empiric prescribing), though this does not create durable brand-level premium once generics are fully aligned on price

2) Price (net realization)

• Continued generic-driven price compression
• Tender cycles that periodically reset pricing downward
• Occasional stabilization where supply constraints or logistics create temporary pricing lift, typically not sustained

3) Mix

• Shift between ceftriaxone use and substitutes is driven by:
  • resistance patterns (e.g., ESBL prevalence)
  • local guideline updates
  • formulary changes

Projection direction (class level):

• Modest volume resilience with ongoing price erosion
• Net effect for brand-level revenue typically flat-to-declining unless the brand holds favorable contracting positions and the supply environment is favorable

---

What key clinical and policy factors will move demand for ceftriaxone?

1. Antimicrobial stewardship intensity

   • Higher stewardship tends to reduce use of broad-spectrum agents when narrow options are available.
   • Stewardship also increases de-escalation after cultures return, lowering duration.

2. Resistance epidemiology

   • Rising resistance reduces empirical ceftriaxone selection in some locales and syndromes.
   • ESBL prevalence can shift practice toward carbapenems in severe cases.

3. Guideline updates

   • When guidelines broaden empiric coverage, ceftriaxone can regain share.
   • When guidelines narrow empiric recommendations, ceftriaxone’s relative share declines.

4. Hospital formulary and tendering

   • Generic competition makes formularies highly price sensitive.
   • ROCEPHIN’s revenue depends on maintaining inclusion and contracting terms.

---

Clinical trial impact vs. utilization impact: where should expectations be set?

For ROCEPHIN, new trials tend to influence:

• Local treatment protocols
• Dosing practices in specific subpopulations
• Comparative pathway selection in certain infection categories

They do not usually change:

• long-run competitive structure (generic competition dominates)
• the pricing floor (tender pricing sets it)
• the regulatory exclusivity profile (ceftriaxone is established)

Model implication: treat clinical trials as a driver of usage mix and duration rather than as a driver of durable brand differentiation.

---

Key Takeaways

• ROCEPHIN (ceftriaxone) sits in a mature, off-patent market where clinical updates mainly shift prescribing patterns, not brand exclusivity.
• Competitive dynamics are dominated by generic multi-source pricing and tendering, limiting brand-level price power.
• Market trajectory for ROCEPHIN-like ceftriaxone brands is best modeled as stable-to-slowly declining revenue driven by price compression offset partially by volume resilience and occasional mix shifts.
• The most material demand movers are stewardship, resistance epidemiology, and guideline/formulary changes, not incremental phase-3 registration trials for the drug substance.

---

FAQs

1) Is ROCEPHIN currently underpinned by new patent-protecting clinical evidence?
No. ROCEPHIN is ceftriaxone, and the product class is largely off-patent, so clinical activity typically does not create brand-level regulatory exclusivity.

2) What is the biggest lever affecting ROCEPHIN revenue in the near term?
Net realization under hospital tender pricing versus generic substitutes.

3) Do resistance trends increase or decrease ceftriaxone use?
Both can occur by locale and syndrome. If resistance reduces susceptibility, clinicians shift away from ceftriaxone; if guidelines broaden empiric coverage, use can rise.

4) Are clinical trials for ceftriaxone likely to change the market structure?
They more commonly change protocols and dosing patterns than alter the competitive structure dominated by generics.

5) How should investors project ceftriaxone class demand?
Use a framework with stable baseline volume, stewardship-driven utilization pressure, continued price erosion, and mix changes tied to resistance and guideline updates.

---

References

[1] FDA. “ROCEPHIN (ceftriaxone for injection) label.” U.S. Food and Drug Administration.
[2] WHO. “WHO Model List of Essential Medicines.” World Health Organization.
[3] CDC. “Antibiotic Use (Stewardship) resources.” Centers for Disease Control and Prevention.
[4] CLSI. “Performance Standards for Antimicrobial Susceptibility Testing.” Clinical and Laboratory Standards Institute.
[5] ECDC. “Antimicrobial resistance surveillance and reporting.” European Centre for Disease Prevention and Control.